We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gottlieb Signals a Sea Change in FDA Risk Management Strategy
Gottlieb Signals a Sea Change in FDA Risk Management Strategy
July 10, 2006
The FDA should step back from its policy of requiring risk management plans (RMP) is part of the drug approval process, according to a senior official — indicating a major change in the agency’s thinking on drug safety.